Roche Alecensa gets USFDA nod for ALK-positive early-stage lung cancer
Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Alecensa (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours ≥ 4 cm or node positive), as detected by an FDA-approved test. “Alecensa is now the first and only ALK inhibitor […]